Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma-Reference-Cited by-同舟云学术

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma

Published:2021-05-31 Issue: Volume: Page:1-24
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Cybulska-Stopa Bożena¹^ORCID,Ziętek Marcin²³,Czarnecka Anna M.⁴⁵,Piejko Karolina¹,Dziura Robert⁶,Galus Łukasz⁷⁸,Ziółkowska Barbara⁹,Kieszko Stanisław¹⁰,Kempa-Kamińska Natasza¹¹,Calik Jacek¹¹,Seredyńska Joanna¹,Gądek Kamila¹,Zemełka Tomasz¹,Teterycz Paweł⁴,Kubiatowski Tomasz¹⁰,Suwiński Rafał⁹,Mackiewicz Jacek⁷¹²,Rutkowski Piotr⁴

Affiliation:

1. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland

2. Department of Oncology, Wrocław Medical University, Wrocław, Poland

3. Department of Surgical Oncology, Wrocław Comprehensive Cancer Center, Wrocław, Poland

4. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

5. Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

6. Clinical Oncology Department, Holy Cross Cancer Center, Kielce, Poland

7. Department of Medical and Experimental Oncology, University of Medical Sciences, Poznan, Poland

8. Chemotherapy Department, Greater Poland Cancer Centre, Poznan, Poland

9. II Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland

10. Department of Clinical Oncology, Saint Jan of Dukla Oncology Centre of the Lublin Region, Lublin, Poland

11. Department of Clinical Oncology, Wrocław Comprehensive Cancer Center, Wroclaw, Poland

12. Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2021.1937477

Reference29 articles.

1. Ugurel S, Rohmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. Eur J Cancer. 2017;83:247-257.

2. Cybulska-Stopa B, Skoczek M, Ziobro M, et al. Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemporary Oncology/Współczesna Onkologia, 16(6), 532-545.

3. Cybulska-Stopa B, Piejko K, Pacholczak R, et al. Real-world treatment practice in patients with advanced melanoma. Contemporary Oncology/Współczesna Onkologia, 24(2), 118-124.

4. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunotherapy Cancer 7, 306 (2019).

5. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer 2015; 3:39.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma;European Journal of Nuclear Medicine and Molecular Imaging;2023-05-04

2. Common statement of experts of the Polish Oncological Society, Polish Lung Cancer Group, Polish Society of Lung Diseases, Polish Society of Gastroenterology, Polish Society of Endocrinology, and the Polish Society of Cardiology for minimal requirements in diagnosis and monitoring of selected adverse events of immunotherapy in oncological patients;Oncology in Clinical Practice;2023-04-21

3. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis;Frontiers in Oncology;2022-09-14

4. Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review;Frontiers in Oncology;2022-08-09

5. CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab;BMC Cancer;2022-04-15